Method for detecting pathological conditions

• US 4,981,783 A
• Filed: 04/16/1986
• Issued: 01/01/1991
• Est. Priority Date: 04/16/1986
• Status: Expired due to Term

• Current Assignee: Montefiore Medical Center
• Original Assignee: Montefiore Medical Center
• Inventors: Augenlicht, Leonard
• Primary Examiner(s): Yarbrough, Amelia Burgess
• Assistant Examiner(s): Marschel, Ardin H.
• Application Number:
  US06/852,401
• Time in Patent Office: 1,721 Days
• Field of Search: 435/6, 435/91, 435/803, 436/501, 436/813, 536/27, 935/3, 935/9, 935/19, 935/29, 935/78, 935/80
• US Class Current: 435/6.11
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 35/028 having reaction cells in the form of microtitration plates
• CPC Class Codes: Y10S 435/803 Physical recovery methods, e.g. chromatography, grinding
• CPC Class Codes: Y10S 436/813 Cancer

Abstract

A method is disclosed for the analysis of gene expression in human biopsy that is useful in the diagnosis and prognosis of disease and evaluation of risk for disease. The method comprises the steps of compiling data regarding the level of expression of certain individual cloned gene sequences from patients having defined pathological conditions and from normal patients and thereafter identifying sequences that characterize the pathological condition.

The data regarding the expression of the individual cloned genes are stored in a defined pattern or array. Replicas of this array are hybridized to radioactive probes made using the RNA isolated from biopsy tissue. The extent of hybridization of the probe to each of the cloned sequences is proportional to the level of expression of the cloned sequence in the tissue from which the probe was made. This may be done by exposing the hybridized clones to x-ray film and scanning the x-ray films to quantify the cloned sequences. This is preferably done with a computer driven scanner. The digitized data may be processed using a computer program. The method may be used to determine the expression of cloned sequences in human colon biopsy samples of malignant of premalignant tissue as well as for monitoring the effects of chemotherapeutic agents.

An apparatus is also disclosed for use in carrying out an automated assay.

Claims

1. A method for the determination of the presence of a malignant or premalignant condition in human tissue or for the determination of risk for development of a malignant or premalignant condition in human tissue, said method comprising the steps of:

(a) isolating RNA from tissue that is to be determined;

(b) preparing a probe using RNA from step (a);

(c) hybridizing to the probe of step (b) a plurality of cloned gene sequences which are unrestricted as to function to form a plurality of hybridized probes;

(d) exposing the hybridized probe to detecting means to quantify the extent of hybridization; and

(e) comparing the extent of the hybridization obtained in step (d) with a known standard to determine the existence of malignant or premalignant tissue or the presence of risk for development of malignant or premalignant condition in human tissue.

2. A method for the determination of the presence of a malignant or premalignant conditions in human tissue as defined in claim 1 wherein the hybridized probe of step (c) is prepared with a material which generates a signal, said material being selected from the group consisting of radioactive probes, immunoreactive probes, or fluorescent probes, phosphoresent probes, luminescent probes or enzymatic probes.

3. A method for the determination of the presence of malignant or premalignant conditions in human tissue as defined in claim 2 wherein the hybridized probe is labeled with a radioactive probe.

4. A method for the determination of the presence of malignant or premalignant conditions in human tissue as defined in claim 3 wherein the detecting means comprise a radioactive probe X-ray films.

5. A method for the determination of the presence of malignant or premalignant conditions in human tissue as defined in claim 4 wherein the film is read by an optical scanner that feeds a signal to a computer that converts the signal to digital form.

6. A method for the determination of the presence of malignant or premalignant conditions as defined in claim 5 wherein the known standard comprises a library of digitized data obtained from a plurality of cloned sequences.

7. A method for the determination of the presence of malignant or premalignant conditions as defined in claim 6 wherein the known standard comprises a plurality of clones derived from RNA from malignant tissue.

8. A method for the determination of the presence of malignant or premalignant condition in human tissue as defined in claim 7 wherein the cloned gene sequences are maintained in a culture of E. coli.

9. A method for the determination of the presence of a malignant or premalignant condition or for the determination of the risk for the development of a malignant or a premalignant condition in human colonic mucosa, said method comprising the steps of:

(a) isolating RNA from human colonic tissue that is to be determined;

(b) preparing a probe using RNA from step (a);

(c) hybridizing the probe from said human colonic tissue to a plurality of cloned gene sequences in a strain of E. coli on filter media, said cloned gene sequences being derived from malignant or premalignant human colon tissue to form a plurality of hybridized probes;

(d) labeling said plurality of hybridized probes with a radioactive tracer;

(e) detecting the degree of hybridization by radiation detecting means that measure the intensity of the tracer on said hybridized probes;

(f) converting the measured intensity of the said tracer to digital data; and

(g) comparing the digital data obtained in step (f) with a known standard to determine the existence of said malignant or premalignant tissue.

10. A method for the determination of the presence of a malignant or premalignant condition in human colonic mucosa as defined in claim 9 wherein the degree of hybridization in step (d) is carried out using X-ray film.

11. A method for the determination of the presence of a malignant or premalignant condition in human colonic mucosa as defined in claim 10 wherein an optical scanner is used to convert images on said X-ray film to digital data.

12. A method for the determination of the presence of a malignant or premalignant condition in human colonic mucosa as defined in claim 11 wherein the digital data is compared with a known standard using computer means.

13. A method for the determination of the presence of a premalignant condition in human tissue or for the determination of risk for development of a premalignant condition in human tissue, said method comprising the steps of:

(a) isolating RNA from tissue that is to be determined;

(b) preparing a probe using RNA from step (a);

(c) hybridizing to the probe of step (b) a plurality of cloned gene sequences, which are unrestricted as to function, from a human colon carcinoma cell line to form a plurality of hybridized probes;

(d) exposing the hybridized probe to detecting means to quantify the extend of hybridization; and

(e) comparing the extent of the hybridization obtained in step (d) with a known standard to determine the existence of premalignant tissue or the presence of risk for development of a premalignant condition in human tissue.